Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinica


Sign up online today & collaborate

or click here to find out more

Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid


Oxford, UK – Summit Therapeutics plc the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and

“Ezutromid has shown great promise in preclinical testing as a universal treatment that has the potential to slow or stop disease progression in all patients with DMD, regardless of their underlying dystrophin gene mutation,” said John Jefferies, MD, of Cincinnati Children’s Hospital Medical Center, and the US coordinating investigator in PhaseOut DMD. “We are excited to participate in PhaseOut DMD and contribute to the clinical development of this utrophin modulator.”

Ralf Rosskamp, MD, Chief Medical Officer of Summit added, “Our PhaseOut DMD clinical trial is an important component of bringing ezutromid to patients and families who are in urgent need of a disease modifying therapy, and we are making progress with patient enrolment in this clinical trial, with enrolment ongoing in the UK and now in the US.”

CompanySummit Therapeutics plc
Company Website

© Catalyst Innovation Portal 2019